The National Institute on Drug Abuse and several national organizations have announced a public health initiative to raise awareness about recent trends in the misuse and abuse of prescription drugs in the United States.
"While prescription drugs can relieve a variety of medical problems and improve the lives of millions of Americans, they can be dangerous, addictive and even deadly when used non-medically," said NIDA Director Alan I. Leshner. "An estimated four million people aged 12 or over used sedatives, stimulants, tranquilizers or opioids for non-medical reasons in 1999."
Joining with the NIDA are the American Association of Retired Persons, the American Academy of Family Physicians, the American Pharmaceutical Association, the National Association of Chain Drug Stores, the National Community Pharmacists Association, the National Council on Patient Information and Education, and the Pharmaceutical Research and Manufacturers of America.
Research suggests that more than 17% of adults over 60 may be affected by prescription drug abuse. New prescription drug abuse has dramatically increased among young people 12 to 25 years old, and in a 1999 survey, 12- to 14-year-olds named psychotherapeutics, such as painkillers, sedatives and stimulants, as some of their more frequently used drugs. Overall, men and women use prescription drugs non-medically in equal numbers.
"Attention must now be paid to the long-neglected area of prescription drug abuse," said Joseph H. Autry III, acting administrator, Substance Abuse and Mental Health Services Administration. "There is no typical abuser. Medical personnel must use every opportunity to screen and educate all of their patients."
As part of this effort, the NIDA and its partners are releasing a research report that highlights the health consequences of prescription drug misuse and abuse.
In addition to the research report, the NIDA is distributing 400,000 postcards with messages about the dangers of prescription drugs. The cards are available in restaurants, book stores, clubs, record stores, coffee shops, gyms and other stores in several major cities and at college campus locations nationwide. PR
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.